sampharm_nt10k-123108.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
SEC FILE
NUMBER 333-39044
_______
NOTIFICATION
OF LATE FILING
(CHECK
ONE): |X| Form 10-K |_| Form
20-F |_| Form 11-K [ ] Form
10-Q
CUSIP
NUMBER
|_|
Form N-SAR
For
Period Ended: December 31, 2008
Transition
Report on Form 10-K [ ]
Transition
Report on Form 20-F [ ]
Transition
Report on Form 11-K [ ]
Transition
Report on Form 10-Q [ ]
Transition
Report on Form N-SAR
For the
Transition Period Ended: _______________________________________
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART I -
REGISTRANT INFORMATION
Samaritan
Pharmaceuticals, Inc.
Full Name
of Registrant
Former
Name if Applicable
2877
Paradise Road, Suite 801
Address
of Principal Executive Officer (Street and Number)
City,
State and Zip Code
PART II -
RULES 12b-25(b) AND (C)
If the
subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to
Rule 12b-25)b), the following should be completed. (Check
box if appropriate) [X] YES [ ] NO
[X] (a)
The reasons described in reasonable detail in Part III of this form could not be
eliminated without unreasonable effort or expense;
[X] (b)
The subject annual report, semi-annual report, transition report on From 10-K,
Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or before the
fifteenth calendar day following the prescribed due date; or the subject
quarterly report of transition report Form 10-Q, or portion thereof will be
filed on or before the fifth calendar day following the prescribed due date;
and
[ ]
(c) The accountant's statement or other exhibit required by Rule 12-b-25(C) has
been attached if applicable.
PART III
- NARRATIVE
State
below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q, N-SAR, or
the transition report or portion thereof, could not be filed within the
prescribed time period. (Attach Extra Sheets if Needed)
The
registrant cannot file its Form 10-K within the prescribed time period because
of pending additional information necessary for finalizing its Form
10-K.
PART IV -
OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this
notification
|
Eugene
J. Boyle
|
702
|
735-7001
|
|
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
(2) Have
all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months (of for such shorter) period
that the registrant was required to file such reports) been filed? If answer is
no, identify report(s). [X] Yes |_|
No
(3) Is
it anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion
thereof? |_| Yes |X| No
If so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Samaritan
Pharmaceuticals, Inc.
(Name of
Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Date:
March 31, 2009
|
By
/s/ Eugene J.
Boyle
|
Eugene J.
Boyle,
Chief
Financial Officer
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See
18 U.S.C. 1001)